New opportunities in the treatment of patients with chronic brain ischemia

Abstract

The study was aimed to evaluate the clinical efficacy of Hericium erinaceus extract (Cebrofit) in combination with vinpocetine compared to vinpocetine monotherapy in patients with chronic cerebral ischemia. Two groups of patients were identified — the basic and control, which included 160 patients with stage I and II dyscirculatory encephalopathy aged 30 to 80 years. All subjects underwent basic therapy, during which for 3 months patients of the basic group took Cebrofit 1 capsule 150 mg twice a day and vinpocetine (Vicebrol) 1 tablet 5 mg three times a day, and patients of the control group used only vinpocetine according to the scheme described above. Based on a comprehensive study, it was found that the use of Cebrofit in combination with vinpocetine compared to vinpocetine monotherapy resulted in accelerated regression of subjective and objective manifestations of chronic brain ischemia with an advantage in patients with stage I dyscirculatory encephalopathy. In patients with stage I dyscirculatory encephalopathy, the use of Cebrofit in combination with vinpocetine produced a pronounced neuroprotective effect, which manifested in a significant improvement in general condition, a decrease in the severity of neurological symptoms, a decrease in the manifestations of asthenia and anxiety after 28 days of therapy, and a significant increase in cognitive performance after 7 days of therapy, while maintaining this positive trend until the end of the course of treatment. In patients with stage II dyscirculatory encephalopathy under the influence of Cebrofit in combination with vinpocetine, positive differences in the form of a decrease in the severity of clinical and neurological symptoms, manifestations of asthenia, anxiety, and depression, as well as improvement in cognitive functions were recorded after 84 days of treatment, which allows recommending the use of these schemes in clinical practice.